Alefacept in corticosteroid refractory graft versus host disease: early results indicate promising activity. J Dermatolog Treat 2007;18(1):13-8
Date
03/17/2007Pubmed ID
17365261DOI
10.1080/09546630601121045Scopus ID
2-s2.0-33947162398 (requires institutional sign-in at Scopus site) 19 CitationsAbstract
Steroid refractory graft versus host disease (GVHD) presents a significant therapeutic challenge due to the limited efficacy and safety of second-line treatments. Three patients with extensively pretreated, refractory GVHD were treated with a targeted anti-T-cell agent, alefacept, and demonstrated rapid and clinically significant improvement in their GVHD, facilitating tapering of corticosteroids. The pathological and immunohistochemical findings of GVHD also improved, validating our clinical impression. These preliminary findings indicate that alefacept may have beneficial activity in GVHD warranting further study.
Author List
Toor AA, Stiff PJ, Nickoloff BJ, Rodriguez T, Klein JL, Gordon KBAuthor
Kenneth Brian Gordon MD Chair, Professor in the Dermatology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Adrenal Cortex HormonesAdult
Aged
Bone Marrow Transplantation
CD2 Antigens
Dermatologic Agents
Female
Graft vs Host Disease
Humans
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Lymphoma, Non-Hodgkin
Male
Middle Aged
Recombinant Fusion Proteins
T-Lymphocytes
Treatment Outcome
